BioCentury
ARTICLE | Clinical News

Taspoglutide: Phase III data

December 21, 2009 8:00 AM UTC

The double-blind, international Phase III T-emerge 7 trial in 305 obese patients with Type II diabetes showed that subcutaneous weekly taspoglutide as an add-on to metformin met the primary endpoint o...